US- based St. Jude Medical has acquired Endosense, a Switzerland-based company for a purchase price of $170m (CHF159m) up-front plus the potential for up to $161m (CHF150m) in subsequent milestone payments. While the acquisition is ...
Endosense, a provider of cardiac technologies, has completed enrolling patients in its Toccastar clinical study. The prospective, randomized, multi-center investigational device exemption trial, which enrolled 300 patients with ...
Tags: Endosense, Toccastar clinical study, cardiac technologies
Endosense has obtained CE mark approval for its TactiCath Quartz force-sensing ablation catheter for the treatment of atrial fibrillation and supraventricular tachycardia. The TactiCath Quartz includes a new force sensor that provides ...
Tags: Endosense, TactiCath Quartz